new glp 1 study shows popular GLP-1 weight loss drug may slow biological aging What do the new 'GLP-1

S2CID 35102048

Furthermore, the study showed that tirzepatide correlated with a marked decrease in the levels of key indicators associated with fibrosis and hypertrophy, such as TGF- , Matrix Metalloprotieinase-9 (MMP9), Collagen Type I Alpha 1 (COLIA1) and F-box only protein 32 (FBXO32) [21]

Therefore, DPP-4 inhibitors may have pleiotropic effects

Mechanistic Studies in Neurodegeneration: Further elucidation of GLP-1RAs neuroprotective mechanisms (eg, anti-inflammatory effects, amelioration of cerebral insulin resistance) is warranted, along with evaluation of the neuropsychiatric potential of GLP-1/GIP dual agonists

Semaglutide is the seventh GLP-1 receptor agonist on the US market and the third dosed once weekly

Contact: Errol Zhou (Mr.) Tel: +86-551-65523315 Mobile/WhatsApp: +86 17705606359 QQ: 196299583 Skype: [email protected] Email: [email protected] Add: 1002, Huanmao Building, No.105, Mengcheng Road, Hefei City, 230061, China Novo Nordisk recently announced the top-line results of the STEP 1 study, which is the second phase IIIa clinical trial completed in the phase III STEP project to evaluate semaglutide's weight loss efficacy